Opinion|Videos|July 18, 2024
Emerging Breast Cancer Therapies and Closing Thoughts
A leading oncologist explores promising new breast cancer therapies in the drug development pipeline and advises healthcare providers on strategies to remain informed about the most current treatment guidelines and recommendations.
Advertisement
Episodes in this series
- What drug developments are targeting unmet needs in breast cancer treatment? What drugs are currently in the pipeline that you are excited about?
- How can healthcare providers stay updated with the latest breast cancer treatment guidelines?
Advertisement
Related to this article
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
4
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
5